Sorry, you need to enable JavaScript to visit this website.

XALACOM (latanoprost and timolol ophthalmic solution (as timolol maleate) Indications And Clinical Use

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.

Indications And Clinical Use

XALACOM (latanoprost and timolol maleate) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-adrenergic blocking agents, prostaglandins, or other IOP lowering agents AND when the use of XALACOM (the combination drug) is considered appropriate.

XALACOM should not be used to initiate therapy.

For details of information obtained from Clinical Trials with XALACOM, please refer to CLINICAL TRIALS section.  Also see DOSAGE AND ADMINISTRATION.

What's New

No Current Announcements.

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111